Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessGilead Sciences (NASDAQ:GILD) Receives "Buy" Rating from Citigroup

Gilead Sciences (NASDAQ:GILD) Receives “Buy” Rating from Citigroup

Add to Favorite
Added to Favorite


Citigroup initiated coverage on Gilead Sciences (NASDAQ:GILD) with a “Buy” rating, reflecting confidence in its innovative HIV, liver diseases, and cancer treatments.
Gilead presented promising results from its Phase 3 PURPOSE 2 trial for lenacapavir, an injectable HIV-1 capsid inhibitor, showcasing its potential in HIV prevention.
Despite positive trial outcomes, GILD’s stock price experienced a slight decrease, highlighting market volatility.

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company known for its innovative treatments in areas such as HIV, liver diseases, and cancer. The company competes with other pharmaceutical giants like Pfizer and Merck. On November 13, 2024, Citigroup initiated coverage on Gilead with a “Buy” rating, indicating confidence in the company’s future performance. At that time, GILD’s stock price was $92.63.

Gilead recently presented results from its Phase 3 PURPOSE 2 trial at the HIV Glasgow conference. This trial evaluates lenacapavir, an injectable HIV-1 capsid inhibitor, administered twice yearly for HIV prevention. The study includes a diverse group of cisgender men and gender-diverse individuals, highlighting Gilead’s commitment to inclusive research.

The trial’s data focuses on adherence rates and the pharmacokinetics of lenacapavir, providing promising insights into its potential as a preventive measure against HIV. This development could enhance Gilead’s portfolio and strengthen its position in the HIV treatment market, supporting Citigroup’s positive outlook on the stock.

Despite the positive trial results, GILD’s stock price has decreased by 1.823%, closing at $92.63. The stock has fluctuated between $91.63 and $94.205 today. Over the past year, GILD has seen a high of $98.9 and a low of $62.07, reflecting market volatility.

Gilead’s market capitalization is approximately $115.3 billion, with a trading volume of 10,776,010 shares. This substantial market cap indicates strong investor interest and confidence in the company’s long-term growth potential, aligning with Citigroup’s “Buy” rating.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Recent Market Movements Highlight Key Company Developments

VCI Global Limited (NASDAQ:VCIG) experienced significant stock price growth...

AXIS Capital Holdings Maintains “Buy” Rating by Cowen & Co.

Cowen & Co. reaffirms a "Buy" rating for NYSE:AXS,...

CrowdStrike Holdings, Inc. (CRWD) Price Target and Financial Performance

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) receives a price target of...

Frontline Ltd. (NYSE:FRO) Faces Market Volatility Amid Optimistic Analyst Projections

Jonathan Chappell from Evercore ISI sets a price target...